FindTrial
Sign In

A clinical trial for zanubrutinib combined with rituximab as a treatment for older patients with diffuse large B-cell lymphoma based on Comprehensive Geriatric Assessment

A clinical trial for zanubrutinib combined with rituximab as a treatment for older patients with diffuse large B-cell lymphoma based on Comprehensive Geriatric Assessment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039342
Enrollment
Unknown
Registered
2020-10-24
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B cell lymphoma

Interventions

experimental group:zanubrutinib combined with rituximab

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients with newly diagnosed CD20+ diffuse large B-cell lymphoma; 2) Aged 60 years or over; 3) received CGA assessment(IACA index); 4) not suitable for standard chemotherapy: IADL = 3, or aged > 75 years; 5) expected life expectancy is over 6 months; 6) liver and kidney function normal.

Exclusion criteria

Exclusion criteria: 1. Patients with a previous history of hematologic malignancy or solid tumor who received chemotherapy or radiation therapy; 2. uncontrolled severe infection; 3. central nervous system or meningeal involvement; 4. with diseases which the researchers considered unsuitable for recruitment; 5. poor compliance.

Design outcomes

Primary

MeasureTime frame
overall response rate;—

Secondary

MeasureTime frame
2-year overall survival;—

Countries

China

Contacts

Public ContactLiu Hui

Beijing Hospital

liuhui8140@126.com+86 13520618812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026